The Pharma Data

APRIL 14, 2021

Xolair for self-injection offers healthcare providers and appr opriate patients another administration option for more flexibility in managing their treatment. with Xolair since its initial approval in 2003. today announced that the U.S. indications. indications. Roche’s Chief Medical Officer and Head of Global Product Development.

FDA Approval 52

FDA Approval Clinical Development FDA Treatment 52

Drug Target Review

DECEMBER 6, 2024

In cases where control or treatment groups show large variability, this could reflect true biological responses to a treatment, and removing such data could reduce the accuracy of the analysis. In 2003, he was selected by EE Times as one of the top 13 most influential people in the semiconductor industry.

RNA 52

RNA Drugs Research Science 52

Drug Target Review

DECEMBER 14, 2023

In 2003, Dr Richard Wood, distinguished Professor at the University of Texas MD Anderson Cancer Center, was a crucial part of the first characterisation of polymerase theta. Polymerase theta TMEJ has been the most elusive DNA repair pathway. Polymerase delta also aids polymerase theta in finishing synthesis.

DNA 59

DNA Clinical Trials Treatment Research 59

The Pharma Data

OCTOBER 21, 2020

Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of next generation drugs for the treatment of cancer. BUFFALO, N.Y., 22, 2020 (GLOBE NEWSWIRE) — Athenex, Inc. About Athenex, Inc.

Engineering 40

Engineering Therapies Treatment International 40

The Pharma Data

OCTOBER 16, 2020

In fact, the number of cases of cancer that had already spread from the prostate to other parts of the body doubled between 2003 and 2017, going from 4% to 8%, according to researchers from the U.S. Understanding prostate cancer rates and survival can help guide treatment and survivor care planning, Siegel said. FRIDAY, Oct.

Medical Schools 52

Medical Schools Treatment Disease Government 52

The Pharma Data

NOVEMBER 18, 2020

” PanCAN leads research initiatives working to transform pancreatic cancer outcomes through early detection and new treatment approaches. Since 2003, the organization has invested $126 million in pancreatic cancer research. This year, it will invest $23 million toward its research initiatives. © 2020 HealthDay.

Disease 52

Disease Treatment Research Trials 52

Drug Target Review

MAY 18, 2023

Results of the Multicenter Study of Hydroxyurea in Sickle Cell Anaemia published in the Journal of the American Medical Association in 2003, indicated that the use of hydroxyurea, the only drug approved at the time, reduced mortality as it reduced pain crises and increased foetal haemoglobin.

Disease 80

Disease Clinical Trials Drugs Trials 80

Drug Target Review

MAY 15, 2024

Of course, with the billions of dollars being invested in AI-led drug discovery programmes, one would think that this is a pivotal moment in patient treatment – like Isomorphic Labs, Recursion, Exscientia, Flagship Pioneering, the big biopharmaceuticals, and even a “$1B+ bet” 2 on Xaira Therapeutics, who have invested heavily in the promise of AI.

FDA Approval 59

FDA Approval FDA Science Marketing 59

The Pharma Data

JANUARY 26, 2021

27, 2021 /PRNewswire/ — BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the European Patent Office (EPO) has issued a decision to grant European patent EP 2 448 968 B1 for novel antibodies that could be developed into a treatment for Alzheimer’s disease. STOCKHOLM , Jan.

Disease 40

Disease Pharmaceutical Companies Treatment Licensing 40

The Pharma Data

JANUARY 25, 2021

BioArctic AB (publ) is a Swedish research-based biopharma company focusing on disease-modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. BioArctic focuses on innovative treatments in areas with high unmet medical needs.

Pharmaceutical Companies 40

Pharmaceutical Companies Disease Treatment Pharmaceuticals 40

The Pharma Data

JANUARY 22, 2021

In the study, IIH rates increased sixfold in Wales between 2003 and 2017 — from 12 per 100,000 people to 76 per 100,000 people. The cause is not fully understood, but weight loss is the main treatment. During the same 15-year span, obesity rates in Wales rose from 29% of the population to 40%. 20 issue of Neurology.

Hospitals 52

Hospitals Doctors Treatment Research 52

PLOS: DNA Science

JULY 27, 2023

That information led, thanks to vaccine shelved from the first SARS circa 2003, to the rapid development and deployment of mRNA vaccines against the new infectious disease. These patterns can foretell which treatments will likely work and which won’t, how likely and quickly the cancer will spread, and its path in the body.

Disease 88

Disease DNA Virus RNA 88

PLOS: DNA Science

OCTOBER 17, 2024

FDA approved a treatment for type 3 of the ultra-rare genetic disease September 20. “Despite extensive research efforts, there have not been approved treatments to meet the significant needs of patients. The original approved was in 2003 to treat a type of Gaucher disease. October is Niemann-Pick Awareness Month.

Disease 52

Disease FDA Approval Drugs Treatment 52

Drug Target Review

SEPTEMBER 11, 2024

What specific advantages do morADC offer in terms of blood-brain barrier penetration and potency, compared to existing treatments? This complex nature of neurodegeneration means that being able to provide a dual targeted therapy in this way could be a significant advantage in treatment.

Small Molecule 52

Small Molecule Disease Therapies Clinical Trials 52

The Pharma Data

FEBRUARY 12, 2022

GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that China’s National Medical Products Administration (NMPA) has approved Benlysta (belimumab) for the treatment of adult patients with active lupus nephritis (LN) who are receiving standard of care. About lupus. Benlysta China Indication.

Production 52

Production Therapies Trials Disease 52

The Pharma Data

DECEMBER 23, 2020

Eligible patients enrolled in the trial receive treatment with AIM’s flagship pipeline drug Ampligen. All study subjects will receive the same Ampligen treatments. In addition, many survivors of the first SARS-CoV-1 epidemic in 2003 continued to report classic chronic fatigue-like symptoms after recovering from the acute illness.

Clinical Trials 52

Clinical Trials Trials Virus Therapies 52

The Pharma Data

JUNE 26, 2021

Food and Drug Administration approved Aduhelm (aducanumab) for the treatment of Alzheimer’s, a debilitating disease affecting 6.2 Aduhelm was approved using the accelerated approval pathway, which can be used for a drug for a serious or life-threatening illness that provides a meaningful therapeutic advantage over existing treatments.

FDA 40

FDA Drugs Therapies Disease 40

The Pharma Data

NOVEMBER 11, 2020

McChesney is the founder and chief executive officer of Cloaked Therapeutics and Arbor Therapeutics, through which he has drawn on more than five decades of research in natural products chemistry to identify and develop novel cancer treatments. In 2009, he established Ironstone Separations Inc.,

Organic Chemistry 52

Organic Chemistry Science Pharmaceuticals Pharmacy 52

The Pharma Data

NOVEMBER 17, 2021

Mike McDermott has been with Pfizer for 18 times having started with the Company in 2003 as head of also Wyeth’s Biotech Manufacturing Operations at its Pearl River, New York point. Over the times he has taken on places with adding situations of responsibility, and he was named President of Pfizer Global Supply in 2019.

Vaccine 52

Vaccine Production Government Treatment 52

The Pharma Data

DECEMBER 8, 2020

The analysis focused on 125 rap songs issued by North American artists, drawn from Top 25 lists issued in 1998, 2003, 2008, 2013 and 2018. These disclosures helped normalize mental health issues and validated getting treatment as a socially acceptable action.” Most of the artists were Black men (78%), with an average age of 28.

Doctors 52

Doctors Treatment Research 52

The Pharma Data

MARCH 26, 2021

The CHMP’s positive opinion brings us one step closer to providing physicians and patients in Europe with the first treatment option specifically designed to work in lupus and lupus nephritis.”. Despite improvements in both diagnosis and treatment over the last few decades, LN remains an indicator of poor prognosis. [3],

Therapies 52

Therapies Treatment Disease Vaccine 52

Drug Target Review

OCTOBER 14, 2024

His current role at Mironid focuses on developing treatments for rare genetic kidney diseases, and his insights reveal the challenges and potential of integrating advanced technologies like artificial intelligence (AI) into the drug discovery process. Raminderpal earned his PhD in semiconductor modelling in 1997.

Science 52

Science Pharmaceutical Companies Drug Development Pharmaceuticals 52

NIH Director's Blog: Drug Development

MARCH 18, 2021

Now, Veesler and his lab are turning to another mammal in their search for new leads for the next generation of antiviral treatments, including ones aimed at the coronavirus that causes COVID-19, SARS-CoV-2. And, how can those structural differences serve as blueprints for promising new treatments to combat many potentially deadly viruses?

Virus 52

Virus Immune Response Clinical Trials Treatment 52

The Pharma Data

JULY 22, 2021

NOTE: ADUHELM TM (aducanumab-avwa)injection 100 mg/mL solutionis indicated for the treatment of Alzheimer’s disease. Treatment with ADUHELM should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. Biogen Inc.

Disease 52

Disease Research Clinical Trials FDA 52

The Pharma Data

NOVEMBER 23, 2020

The study is an open-label, exploratory phase I/II trial adding ONCOS-102 to SoC chemotherapy (pemetrexed/cisplatin) in first- and second- (and later) line treatment of MPM to assess safety, immune activation and efficacy versus SoC only. 1 Vogelzang 2003, Ceresoli 2006, Zalcman 2015, Tsao 2019, Scagliotti 2019, Baas 2020 SITC 2020 poster.

FDA Approval 40

FDA Approval Trials Treatment Virus 40

NIH Director's Blog: Drug Development

MAY 21, 2020

Because of these and other factors, many experts think antibody-based therapies may offer one of the best near-term options for developing safe, effective treatments for COVID-19. So, what exactly led up to this latest scientific achievement?

Virus 52

Virus Vaccine Laboratories Small Molecule 52

The Pharma Data

MAY 5, 2021

GlaxoSmithKline plc (GSK) today announced the European Commission has approved the expanded use of intravenous and subcutaneous BENLYSTA (belimumab) in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis (LN) in Europe, in addition to systemic lupus erythematosus (SLE).

Therapies 52

Therapies Disease Treatment International 52

Codon

AUGUST 27, 2024

In 2003, the DHS launched the BioWatch program after five people died and twenty fell ill from touching envelopes laced with anthrax spores. Putting a sequencer in every port, hospital, water treatment plant, or subway station isn’t feasible just yet due to the expense.

DNA 84

DNA Laboratories Hospitals Virus 84

Perficient: Drug Development

JANUARY 25, 2024

This is a disappointing reversal for payers, as the 2010 results showed a nine-point gain compared to the 2003 figure. Understand the role consumers want you to play In the past, we’ve seen payers provide detailed information on common conditions and treatments covered by their health plans.

Nurses 52

Nurses Health Insurance Companies Pharmaceutical Companies Hospitals 52

The Premier Consulting Blog

DECEMBER 28, 2023

3] Understanding Medicare Coverage for IDE Studies The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) allows for Medicare coverage of the routine costs of care provided to Medicare beneficiaries in certain categories of Investigational Device Exemption (IDE) studies. [4]

Regulations 52

Regulations FDA Clinical Trials Packaging 52

The Premier Consulting Blog

JANUARY 17, 2023

The Pediatric Research Equity Act (PREA) was signed into law in 2003 to increase pediatric use information in product labeling and close knowledge gaps regarding the safety, efficacy, and appropriate dosing of drugs to treat children.

Production 52

Production Clinical Trials FDA Disease 52

The Pharma Data

NOVEMBER 9, 2020

Additionally, the vast majority of patients only receive a temporary benefit or no benefit from ICIs, as they either develop resistance to the treatment during the course of therapy or are non-responsive to the treatment altogether (only 15%-20% of patients respond, according to published data). Next Steps in Immunotherapy.

Immune Response 40

Immune Response Therapies Clinical Trials Treatment 40

The Pharma Data

OCTOBER 19, 2020

In February 2020, the United States Food and Drug Administration granted the regulatory Fast Track designation for the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, for the treatment of patients with locally advanced head and neck squamous cell cancer who are not eligible for platinum-based chemotherapy.

Clinical Trials 40

Clinical Trials Immune Response Trials Therapies 40

Codon

DECEMBER 17, 2023

A first draft of the human genome was completed in 2003. In Switzerland, although evidence for the efficacy of iodized salt was robust, some eminent scientists spoke out against the interventions—advocating for elaborate alternative treatments. CRISPR gene-editing was invented in 2012 and applied to human embryos soon after.

Engineering 52

Engineering Molecular Biology Doctors DNA 52

Agency IQ

NOVEMBER 20, 2023

EPA publishes draft Meaningful Involvement Policy The Environmental Protection Agency has released a draft of its Meaningful Involvement Policy, an update of a 2003 policy, which seeks to improve the interactions of the agency with stakeholders about agency actions.

Regulations 40

Regulations Government International Science 40

FDA Law Blog: Biosimilars

FEBRUARY 27, 2024

FDA also approved two NDAs on the same first day for micafungin (MYCAMINE)—NDA 021506 for prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation, and NDA 021754 for the treatment of esophageal candidiasis. 2003) , and Biogen lnt’l v. Patent Nos. Ezra Ventures LLC, 909 F.3d 3d 1367 (Fed.

FDA Approval 59

FDA Approval FDA Production Therapies 59

The Pharma Data

FEBRUARY 25, 2021

5 Currently there is no cure or treatment for TBE, only management of symptoms. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. 2003 Dec 12;22(2):217-23. 2%; up to 20% in Russia), people may die.

FDA 52

FDA Vaccine Virus Clinical Trials 52